How emotive supports companies launching advanced therapies

We are dedicated to advanced therapies & innovative treatments

At emotive, our simple vision is to transform lives by inspiring change that has a positive impact on people’s health. We offer an individual approach for companies developing advanced therapy medicinal products (ATMPs) and other innovative treatments for rare disorders to help them stimulate advocacy, uptake and access.

We are experienced in rare diseases

With over 50% of our medical communications work dedicated to rare and ultra-rare disorders, many with orphan indications, we know rare disorders have their own unique complexities and challenges. Deficits in disease awareness are a significant issue in rare disorders, contributing to diagnostic delays and convoluted patient journeys. Promoting awareness of rare diseases and novel therapies across the stakeholder continuum is essential in ensuring patients can achieve appropriate and timely support. ?At emotive we have developed a wealth of experience in the rare disease space, supporting clients across a wide range of disorders and indications at all stages of the product lifecycle.

We have expertise in advanced therapies

As some 80% of rare diseases are genetic in origin, they represent an obvious target for advanced therapies capable of targeting the cause of the disease. ATMPs hold remarkable promise in terms of addressing unmet patient needs with one-off treatments and long-term benefits, yet their revolutionary nature necessitates unique considerations spanning research and development through to commercialisation. Limitations on clinical data due to small patient populations, distinct manufacturing and logistics concerns, specialised diagnosis, treatment and referral pathways, country-specific launches and cross-border healthcare all come into play when ensuring patients can gain access to transformative treatments.

We are currently working with several clients in the ATMP field across both cell and gene therapies, including recently supporting in the launch of one of the few approved in vivo gene therapies. We are supporting these clients at a global level to create enhanced communication strategies, messages and tactics to achieve engagement, improve confidence and maximise collaboration amongst patients and caregivers, HCPs, payers and other key stakeholders in the care pathway. Some key activities we have developed for clients over the last year include:

• Creation of suites of MSL materials to reinforce a consistent narrative around rare disorders and advanced therapy treatments
• Development and coordination of global symposia to help raise awareness of rare disorders
• Building of internal eLearning programmes to educate field teams on the disease area, advanced therapy treatment, competitive landscape and latest clinical trial data
• Development of insight-driven, targeted disease awareness campaigns delivered to specialist HCPs, GPs and patients to support the launch of ATMPs
• Facilitation of expert forums and screening strategy workshops with KOLs to understand the challenge and unmet needs in a disease area and helped them agree on the best practice for identifying patients suspected of having rare disorders
• Organisation of international exchange meetings between the multidisciplinary teams of different hospitals to share best practices on ATMP administration
• Production of HCP and patient/caregiver-focussed educational materials highlighting the burden of disease and recommendations for post-treatment care

We have in-house experts in ATMP communications

At emotive, we have extensive scientific and management experience in cell and gene therapies with an international network of ATMP scientists and medical professionals. With access to the wider emotive team and the specialist market access & HEOR support within Synaptiq Health, clients are able to leverage highly skilled colleagues, including pharmacists, and academics with scientific, medical, commercial, market access and creative expertise.

emotive is a global healthcare communications agency who partner with health-focused companies across medical & scientific affairs, brand & patient engagement and PR & advocacy.

Fifteen years ago, we started on our journey to transform lives by inspiring change that has a positive impact on people’s health.

Today, with significant expertise in multiple therapy areas, rare diseases and advanced therapies, we continue to inspire change by driving advocacy and uptake of life-changing products, brands and services.

With the very best scientific, creative and digital minds, our team bring huge experience in medical, marketing, technology, public relations and advocacy to provide leading healthcare communications support to all our client partnerships.

If you would like to find out more about joining emotive, please contact?[email protected]. For more information on our services, contact?[email protected]